Shifeng Pan, Ph.D.

Chief Scientific Officer

Shifeng Pan, Ph.D., Chief Scientific Officer at Genesis Therapeutics Shifeng brings to Genesis more than two decades of experience in drug discovery across multiple therapeutic areas, which includes a 22-year career at Novartis, where he served as the Head of Discovery Chemistry at the Genomics Institute of the Novartis Research Foundation. There, he led the discovery of FDA-approved drugs ODOMZO®, BRAFTOVI®, and MAYZENT®, as well as numerous other programs across several therapeutic areas. Shifeng comes to Genesis from Odyssey Therapeutics, where he was Executive Vice President and Head of Discovery. He holds a Ph.D. in organic chemistry from New York University.